Nedosiran (DCR-PHXC) is a GalNAc-dsRNA conjugate designed for RNA interference-based silencing of lactate dehydrogenase (LDH), enabling selective hepatic targeting and reduction of oxalate production, Nedosiran is extensively studied as a potential therapeutic approach for patients with primary hyperoxaluria and end-stage renal disease to address metabolic dysregulation at the RNA level.
CAS Nummer:
[2266591-83-5]
Target-Kategorie:
Dehydrogenase
T39802
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
